产品
编 号：F762676
分子式：C24H31DBrN5O7
分子量：583.45
分子式：C24H31DBrN5O7
分子量：583.45
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 2779498-79-0
产品详情
生物活性：
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
体内研究：
VV116 (25, 50 and 100 mg/kg; PO; b.i.d for 4 days) exhibits a stronger activity and decreases the virus titers below the detection limit at 50 mg/kg, also reduces lung injury after RSV infection.VV116 (25, 50 and 100 mg/kg; PO; single dosage) exhibits favorable PK properties and good safety profile.Pharmacokinetic Parameters of VV116 (JT001) in Balb/c mice.PO (25 mg/kg) PO (50 mg/kg) PO (100 mg/kg)
Tmax (h)0.42 ± 0.140.42 ± 0.140.42 ± 0.14
Cmax (ng/mL)5360 ± 56011617 ± 344324017 ± 6521
AUC0-t (ng/mL·h)11461 ± 101324594 ± 105947799 ± 6545
AUC0-∞ (ng/mL·h)11534 ± 99224739 ± 102848014 ± 6696
MRT0-∞ (ng/mL·h)2.25 ± 0.322.15 ± 0.262.28 ± 0.53
Tmax (h)2.30 ± 1.103.27 ± 1.924.25 ± 0.53
Animal Model:Balb/c mice
Dosage:25, 50 and 100 mg/kg
Administration:PO; single dosage (Pharmacokinetics Analysis)
Result:Exhibited favorable PK properties and good safety profile.
Animal Model:Balb/c mice (6-8 weeks; intranasally infected with 4?×?10^6 FFU of RSV)
Dosage:25, 50 and 100 mg/kg
Administration:PO; b.i.d for 4 days
Result:Exhibited a stronger activity and decreased the virus titers below the detection limit at 50 mg/kg, also reduced lung injury after RSV infection.
体外研究：
氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱。氘代化合物的潜在优势：（1）延长体内半衰期。氘代化合物或能够延长化合物的药代动力学特征，即延长体内半衰期。由此可提高化合物安全性、有效性和耐受性，并增加给药的便捷性。（2）提高口服生物利用度。氘代化合物或能够减少肠壁和肝脏中不需要的代谢 (首过代谢) 程度，使得更大比例的未代谢药物到达作用的目标位置。生物利用度高决定其在低剂量下具有活性以及更好的耐受性。（3）改善代谢特征。氘代化合物或能够减少有毒或反应性代谢物的形成，改善药物代谢状况。（4）改进药品安全性。氘代化合物或能够减少或消除药物化合物的不良副作用，具有安全性。（5）保留治疗特性。氘代化合物有望保留和此前研究中氢类似物相似的生化效力和选择性。
Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
体内研究：
VV116 (25, 50 and 100 mg/kg; PO; b.i.d for 4 days) exhibits a stronger activity and decreases the virus titers below the detection limit at 50 mg/kg, also reduces lung injury after RSV infection.VV116 (25, 50 and 100 mg/kg; PO; single dosage) exhibits favorable PK properties and good safety profile.Pharmacokinetic Parameters of VV116 (JT001) in Balb/c mice.PO (25 mg/kg) PO (50 mg/kg) PO (100 mg/kg)
Tmax (h)0.42 ± 0.140.42 ± 0.140.42 ± 0.14
Cmax (ng/mL)5360 ± 56011617 ± 344324017 ± 6521
AUC0-t (ng/mL·h)11461 ± 101324594 ± 105947799 ± 6545
AUC0-∞ (ng/mL·h)11534 ± 99224739 ± 102848014 ± 6696
MRT0-∞ (ng/mL·h)2.25 ± 0.322.15 ± 0.262.28 ± 0.53
Tmax (h)2.30 ± 1.103.27 ± 1.924.25 ± 0.53
Animal Model:Balb/c mice
Dosage:25, 50 and 100 mg/kg
Administration:PO; single dosage (Pharmacokinetics Analysis)
Result:Exhibited favorable PK properties and good safety profile.
Animal Model:Balb/c mice (6-8 weeks; intranasally infected with 4?×?10^6 FFU of RSV)
Dosage:25, 50 and 100 mg/kg
Administration:PO; b.i.d for 4 days
Result:Exhibited a stronger activity and decreased the virus titers below the detection limit at 50 mg/kg, also reduced lung injury after RSV infection.
体外研究：
氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱。氘代化合物的潜在优势：（1）延长体内半衰期。氘代化合物或能够延长化合物的药代动力学特征，即延长体内半衰期。由此可提高化合物安全性、有效性和耐受性，并增加给药的便捷性。（2）提高口服生物利用度。氘代化合物或能够减少肠壁和肝脏中不需要的代谢 (首过代谢) 程度，使得更大比例的未代谢药物到达作用的目标位置。生物利用度高决定其在低剂量下具有活性以及更好的耐受性。（3）改善代谢特征。氘代化合物或能够减少有毒或反应性代谢物的形成，改善药物代谢状况。（4）改进药品安全性。氘代化合物或能够减少或消除药物化合物的不良副作用，具有安全性。（5）保留治疗特性。氘代化合物有望保留和此前研究中氢类似物相似的生化效力和选择性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备